Modification of the estrogenic properties of diphenols by the incorporation of ferrocene. Generation of antiproliferative effects in vitro

Journal of Medicinal Chemistry

Volumn 48, Issue 12, 2005, Pages 3937-3940

  Vessières, Anne ^a   Top, Siden ^a   Pigeon, Pascal ^a   Hillard, Elizabeth ^a   Boubeker, Leila ^a   Spera, Daniela ^a   Jaouen, Gérard ^a  

^a PSL RESEARCH UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,1 BIS (4' HYDROXYPHENYL) 2 PHENYLBUT 1 ENE; 1,1 BIS(4' HYDROXYPHENYL) 2 FERROCENYL BUT 1 ENE; 1,2 BIS(4' HYDROXYPHENYL) 2 FERROCENYL BUT 1 ENE; 3,4 BIS (4' HYDROXYPHENYL) 3 HEXENE; CYTOTOXIC AGENT; ESTROGEN RECEPTOR ALPHA; FERROCENE DERIVATIVE; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ESTROGEN ACTIVITY; HORMONE DEPENDENCE; HUMAN; HUMAN CELL; NUCLEAR MAGNETIC RESONANCE; OXIDATION; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; FEMALE; FERROUS COMPOUNDS; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; ORGANOMETALLIC COMPOUNDS; PHENOLS; STRUCTURE-ACTIVITY RELATIONSHIP; UTERUS;

EID: 20444389353     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050251o     Document Type: Article

References (31)

1. Haslam, E. Practical Polyphenolics-From Structure to Molecular Recognition and Physiological Action; Cambridge University Press: Cambridge, 1998.
2. Okuda, T.; Yoshida, T.; Hatano, T. Hydrolyzable tannins and related polyphenols. Prog. Chem. Org. Nat. Prod. 1995, 66, 1-117.
3. Santos-Buelga, C.; Williamson, G. Methods in Polyphenol Analysis; RSC: Cambridge, 2003.
4. Corder, R.; Douthwaite, J. A.; Lees, D. M.; Khan, N. Q.; Visen dos Santos, A. C.; Wood, E. E.; Carrier, M. J. Red wines confer extra benefit when it comes to preventing coronary heart disease. Nature 2001, 414, 863-864.
5. Frémont, L. Biological effects of resveratrol. Life Sci. 2000, 66, 663-673.
6. Quideau, S. Plant Polyphenolic Small Molecules Can Induce a Calorie Restriction-Mimetic Life-Span Extension by Activating Sirtuins: Will Polyphenols Someday Be Used as Chemotherapeutic Drugs in Western Medicine? ChemBiochem 2004, 427-430.
7. Mueller, S. O.; Simon, S.; Chae, K.; Metzler, M.; Korach, K. S. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol. Sci. 2004, 80, 14-25.
8. Bowers, J. L.; Tyulmenkoy, V. V.; Jernigan, S. C.; Klinge, C. M. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 2000, 141, 3657-3667.
9. Gehm, B. D.; Levenson, A. S.; Liu, H.; Lee, E. J.; Amundsen, B. M.; Cushman, M.; Jordan, V. C.; Jameson, J. L. Estrogenic effects of resveratrol in breast cancer cells expressing mutant and wild-type estrogen receptors: role of AF-1 and AF-2. J. Steroid Biochem. Mol. Biol. 2004, 88, 223-234.
10. M. J.; Duncan, J. Effects of trans-resveratrol on copper-dependent hydroxyl-radical formation and DNA damage: evidence for hydroxyl-radical scavenging and a novel, glutathione-sparing mechanism of action. Arch. Biochem. Biophys. 2000, 381, 253-263.
11. Holmes-McNary, M.; Baldwin, A. S. J. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res. 2000, 60, 3477-3483.
12. Van Lipzig, M. M. H.; ter Laak, A. M.; Jongejan, A.; Vermeulen, N. P. E.; Wamelink, M.; Geerke, D.; Meerman, J. H. N. Prediction of Ligand Binding Affinity and Orientation of Xenoestrogens to the Estrogen Receptor by Molecular Dynamics Simulations and the Linear Interaction Energy Method. J. Med. Chem. 2004, 47, 1018.
13. Giusti, R. M.; Iwamoto, K.; Hatch, E. E. Diethylstilbestrol revisited: a review of the long-term health effects. Ann. Intern. Med. 1995, 122, 778-788.
14. Schrager, S.; Potter, B. E. Diethylstilbestrol exposure. Am. Fam. Physician 2004, 69, 2395-2400.
15. (a) Lubczyk, H.; Bachmann, R.; Gust, R. Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity. J. Med Chem. 2003, 46, 1484-1491.
16. (b) Schneider, M. R.; Von Angerer, E.; Schönenberger, H.; Michel, R. T.; Fortmeyer, H. P. 1,1,2-triphenylbut-1-enes: relationship between structure, estradiol receptor affinity, and mammary tumor inhibiting properties. J. Med. Chem. 1982, 25, 1070-1077.
17. Stoessel, S.; Leclercq, G. Competitive binding assay for estrogen receptor in monolayer culture: measure of receptor activity potency. J. Steroid Biochem. 1986, 25, 677-682.
18. Jaouen, G.; Top, S.; Vessières, A.; Leclercq, G.; McGlinchey, M. J. The first organometallic selective estrogen receptor modulators (SERMs) and their relevance to breast cancer. Curr. Med. Chem. 2004, 11, 2505-2517.
19. Top, S.; Vessières, A.; Pigeon, P.; Rager, M. N.; Huché, M.; Salomon, E.; Cabestaing, C.; Vaissermann, J.; Jaouen, G. Selective estrogen receptor modulators (SERMs) in the cyclopentadienyl rhenium tricarbonyl series. Synthesis and Biological behaviour. ChemBioChem 2004, 5, 1104-1113.
20. Top, S.; Vessières, A.; Leclercq, G.; Quivy, J.; Tang, J.; Vaissermann, J.; Huché, M.; Jaouen, G. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines. Chem. Eur. J. 2003, 9, 5223-5236.
21. Osella, D.; Ferrali, M.; Zanello, P.; Laschi, F.; Fontani, M.; Nervi, C.; Cavigiolio, G. On the mechanism of the antitumor activity of ferrocenium derivatives. Inorg. Chim. Acta 2000, 306, 42-48.
22. Tamura, H.; Miwa, M. DNA cleaving activity and cytotoxic activity of ferricenium cations. Chem. Lett. 1997, 1177-1178.
23. Fan, P. W.; Zhang, F.; Bolton, J. L. 4-hydroxylated metabolites of the antiestrogens tamoxifen and toremifene are metabolized to unusually stable quinone methides. Chem. Res. Toxicol. 2000, 13, 45-52.
24. Zhang, F.; Fan, P. W.; Liu, X.; Shen, L.; van Breeman, R. B.; Bolton, J. L. Synthesis and reactivity of a potential carcinogenic metabolite of tamoxifen, 3,4-dihydroxytamoxifen-o-quinone. Chem. Res. Toxicol. 2000, 13, 53-62.
25. Yu, L.; Liu, H.; Li, W.; Zhang, F.; Luckie, C.; van Breemen, R. B.; Thatcher, G. R.; Bolton, J. L. Oxidation of raloxifene to quinoids: potential toxic pathways via a diquinone methide and o-quinones. Chem. Res. Toxicol. 2004, 17, 879-888.
26. Amatore, C.; Hillard, E. A.; Jaouen, G.; Thouin, L.; Vessières, A. Ferrocene-mediated proton-coupled electron transfer in a series of ferrocifen-type breast cancer drug candidates. Manuscript in preparation.
27. Kurihara, M.; Sano, H.; M., M.; Nishihara, H. Synthesis of a vinylene-bridged ferrocene-hydroquinone complex and its unusual structural change originated by proton-coupled electron transfer. Inorg. Chem. 2001, 40, 4-5.
28. Montano, M. M.; Jaiswal, A. K.; Katzenellenbogen, B. S. Transcriptional regulation of the human quinone reductase gene by antiestrogen-liganded estrogen receptor alpha and estrogen receptor beta. J. Biol. Chem. 1998, 273, 25443-25449.
29. Yang, S. H.; Liu, R.; Perez, E. J.; Wen, Y.; Stevens, S. M.; Valencia, T.; Brun-Zinkernagel, A. M.; Prokai, L.; Will, Y.; Dykens, J.; Koulen, P.; Simpkins, J. W. Mitochondrial localization of estrogen receptor β. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 4130-4135.
30. Vladusic, E. A.; Hornby, A. E.; Guerra-Vladusic, F. K.; Lupu, R. Expression of estrogen receptor β messenger RNA variant in breast cancer. Cancer Res. 1998, 58, 210-214.
31. Palmieri, C.; Cheng, G. J.; Saji, S.; Zelada-Hedman, M.; Wärri, A.; Weihua, Z.; Van Noorden, S.; Wahlstrom, T.; Coombes, R. C.; Warner, M.; Gustafsson, J. A. Estrogen receptor beta in breast cancer. Endocr. Relat. Cancer 2002, 9, 1-3.